GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Land And Improvements

CTNM (Contineum Therapeutics) Land And Improvements : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Land And Improvements?

Contineum Therapeutics's land and improvements for the quarter that ended in Dec. 2024 was $0.00 Mil.


Contineum Therapeutics Land And Improvements Historical Data

The historical data trend for Contineum Therapeutics's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Land And Improvements Chart

Contineum Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Land And Improvements
- - - -

Contineum Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Contineum Therapeutics Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.


Contineum Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3565 General Atomics Court, Suite 200, San Diego, CA, USA, 92121
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.